Edwin DeJesus Selected Research

elvitegravir

9/2016	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials.
6/2015	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
3/2014	A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
5/2013	A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
4/2013	A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
6/2012	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
3/2011	Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edwin DeJesus Research Topics

Disease

39	Infections 12/2022 - 10/2003
12	HIV Infections (HIV Infection) 01/2021 - 08/2004
8	Nausea 01/2020 - 08/2003
4	Headache (Headaches) 10/2021 - 01/2018
3	Viremia 01/2022 - 06/2013
3	Coinfection 01/2020 - 03/2015
3	Virus Diseases (Viral Diseases) 11/2013 - 10/2003
3	Hypersensitivity (Allergy) 09/2006 - 01/2005
2	Weight Gain 01/2020 - 06/2007
2	Chronic Hepatitis C 01/2017 - 01/2016
2	Fibrosis (Cirrhosis) 01/2016 - 03/2015
2	Proteinuria 06/2015 - 10/2008
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2014 - 06/2013
2	Exanthema (Rash) 06/2012 - 03/2010
2	Dizziness (Lightheadedness) 06/2012 - 08/2003
2	Hyperbilirubinemia 05/2012 - 03/2010
2	Diarrhea 03/2010 - 05/2006
2	Acquired Immunodeficiency Syndrome (AIDS) 10/2007 - 06/2007
2	Disease Progression 05/2006 - 09/2002
1	COVID-19 12/2021
1	Pain (Aches) 10/2021
1	Drug-Related Side Effects and Adverse Reactions 11/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020
1	Hypotension (Low Blood Pressure) 04/2019
1	Pulmonary Arterial Hypertension 04/2019
1	Myocardial Infarction 01/2018
1	Renal Colic 01/2018
1	Neutropenia 01/2018
1	Chronic Hepatitis B 11/2017
1	Hepatitis C 11/2017
1	Urticaria (Hives) 01/2017
1	Angioedema 02/2016
1	Renal Insufficiency (Renal Failure) 06/2015
1	Hepatocellular Carcinoma (Hepatoma) 03/2015
1	Liver Diseases (Liver Disease) 03/2015
1	Persistent Infection 11/2014
1	Gilbert Disease 01/2014
1	Necrosis 01/2014

Drug/Important Bio-Agent (IBA)

19	Emtricitabine (Emtriva)FDA Link 01/2020 - 01/2006
17	Tenofovir (Viread)FDA Link 01/2020 - 07/2004
11	tenofovir alafenamideIBA 01/2020 - 06/2015
8	RNA (Ribonucleic Acid)IBA 12/2022 - 01/2005
8	Ritonavir (Norvir)FDA Link 01/2020 - 05/2006
8	CobicistatIBA 01/2020 - 03/2011
8	efavirenz (Sustiva)FDA Link 01/2017 - 08/2004
7	Pharmaceutical PreparationsIBA 01/2018 - 09/2002
7	elvitegravirIBA 09/2016 - 03/2011
6	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 01/2005
5	VaccinesIBA 12/2021 - 11/2013
5	Lamivudine (Epivir)FDA Link 01/2021 - 08/2004
5	abacavir (Ziagen)FDA Link 01/2020 - 01/2005
5	TabletsIBA 01/2019 - 03/2011
5	Atazanavir Sulfate (Reyataz)FDA Link 03/2014 - 03/2008
4	NucleosidesIBA 01/2021 - 09/2004
4	bictegravirIBA 01/2020 - 01/2017
4	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 11/2014
4	Zidovudine (Retrovir)FDA LinkGeneric 11/2006 - 08/2004
4	lamivudine drug combination abacavir FDA Link 11/2006 - 05/2006
3	doravirineIBA 01/2021 - 01/2018
3	Antiviral Agents (Antivirals)IBA 01/2020 - 05/2006
3	dolutegravirIBA 01/2020 - 01/2017
3	Reverse Transcriptase InhibitorsIBA 01/2018 - 09/2004
3	SimeprevirIBA 01/2017 - 11/2014
3	RacivirIBA 06/2012 - 05/2012
3	fosamprenavir (Lexiva)FDA Link 03/2008 - 05/2006
2	CholesterolIBA 01/2020 - 01/2005
2	Darunavir (Prezista)FDA Link 01/2020 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 11/2013
2	Rilpivirine (TMC-278)IBA 01/2017 - 01/2017
2	SofosbuvirIBA 01/2016 - 11/2014
2	NucleotidesIBA 01/2016 - 09/2004
2	CreatinineIBA 06/2015 - 10/2008
2	Biomarkers (Surrogate Marker)IBA 01/2014 - 06/2013
2	Enfuvirtide (Fuzeon)FDA Link 12/2008 - 08/2003
2	LipidsIBA 01/2005 - 07/2004
1	Broadly Neutralizing AntibodiesIBA 01/2022
1	ChAdOx1 nCoV-19IBA 12/2021
1	Monoclonal AntibodiesIBA 10/2021
1	islatravirIBA 01/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021
1	vesatolimodIBA 01/2021
1	fostemsavirIBA 01/2020
1	oxidized low density lipoproteinIBA 01/2020
1	HLA-B Antigens (HLA-B)IBA 01/2020
1	GSK-2838232IBA 01/2020
1	IgG Receptors (Fc gamma RI)IBA 11/2019
1	riociguatIBA 04/2019
1	Soluble Guanylyl CyclaseIBA 04/2019
1	emtricitabine tenofovir alafenamideIBA 01/2019
1	cobicistat mixture with darunavirIBA 01/2019
1	acivicin (AT 125)IBA 01/2018
1	elbasvirIBA 03/2015
1	grazoprevirIBA 03/2015
1	InterferonsIBA 11/2014
1	UK 453,061IBA 09/2014
1	etravirine (TMC-125)FDA Link 09/2014
1	C-Reactive ProteinIBA 01/2014
1	BilirubinIBA 01/2014

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2006
1	Intravenous Injections 10/2021